Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD, PrecisionCHD and the HeartRisk population insights platform. These tools are designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
Cardiovascular disease remains a leading driver of health plan costs and workforce productivity losses. By integrating artificial intelligence with genetic and epigenetic data, Cardio Diagnostics aims to provide more personalized and precise prevention and detection strategies. The company's participation in these conferences underscores the growing interest among employers and benefit plan sponsors in proactive health management solutions that can reduce long-term expenditures.
The conferences will provide a platform for Cardio Diagnostics to demonstrate how its technology can identify high-risk individuals before costly events occur. The company's offerings include Epi+Gen CHD, a test that combines genetic and epigenetic markers to assess coronary heart disease risk; PrecisionCHD, which provides a comprehensive risk score; and HeartRisk, a population analytics tool that enables employers to understand cardiovascular risk across their workforce.
According to the company, early detection and intervention can significantly reduce the incidence of heart attacks and strokes, which are among the most expensive medical conditions to treat. By targeting prevention, employers may lower their healthcare spending while improving employee health and productivity.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company. It was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The company aims to become a leading medical technology company for improving prevention, detection, and treatment of cardiovascular disease.
For more information, visit the company's newsroom at https://ibn.fm/CDIO. The full press release is available at https://ibn.fm/qFRHu. Please see full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
